Pediatric Study Group Publish Paper on Lack of Efficacy of Bevacizumab Plus Irinotecan in Pediatric Recurrent Ependymoma

— Categories: Ependymoma Research Articles     Posted on November 14, 2012

This study, conducted by the Pediatric Brain Tumor Consortium, was one component of a wider effort to study the efficacy of bevacizumab in combination with a conventional chemotherapeutic agent (here irinotecan) to treat children with recurrent brain tumors.

These studies were stimulated by early, promising results from clinical trials of similar combination therapy among adults with brain tumors. Unfortunately, the treatment had no evident impact on the survival of children with ependymoma; highlighting the importance to identify new efficacious treatments and underscoring the different biologys that drive different types of brain tumor.

Read the PubMed Article, click here.

Stay Informed with the CERN Newsletter

The CERN Foundation is committed to informing you with the latest ependymoma news and research. Join our mailing list for monthly updates.